Loading…
← CockpitCompetitor Analysis › MNKD MannKind CorporationOpen in the cockpit ↗

MannKind CorporationMNKDCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Makes Afrezza inhaled insulin and manufactures Tyvaso DPI, an inhaled pulmonary hypertension drug, for United Therapeutics.

Momentum leader 86
Mkt cap
$1.31B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$12.7M
20-day average traded
Fwd P/E
174.4×
forward earnings
ROIC−WACC
-11.4 pp
WACC 9.3%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$4.07
1D0.0%
1W-2.9%
1M+31.3%
3M-4.5%
6M+25.2%
YTD-28.2%
1Y-18.3%
ATR %4.9%
Beta1.08
52w lowhigh37.5% off high

What MannKind does

Makes Afrezza inhaled insulin and manufactures Tyvaso DPI, an inhaled pulmonary hypertension drug, for United Therapeutics.

Collects a royalty on United Therapeutics' sales of Tyvaso DPI and also manufactures the product for it, while selling Afrezza itself. Both rest on its Technosphere dry-powder inhalation technology, so the partner's sales and its own plant capacity matter.

Products and services

  • Afrezza (inhaled insulin)
  • Tyvaso DPI manufacturing (for United Therapeutics)
  • Other inhaled drug partnerships

Customers

  • Diabetes patients/endocrinologists
  • United Therapeutics (manufacturing partner)

Where it sits in the supply chain

  • Specialty pharmaceuticals
  • Inhaled drug-delivery technology…
  • Diabetes + partnered respiratory…

What could go right

  • Tyvaso DPI royalty/manufacturing revenue growth
  • Afrezza prescription growth

What could go wrong

  • Afrezza's slow historical adoption vs injectable insulin
  • Revenue concentration in United Therapeutics partnership

Moat: narrow (IP / patents, process know-how). Proprietary Technosphere inhaled-powder platform is patent-protected and manufacturing-intensive to replicate.

Headquarters: Danbury, Connecticut, US · Founded: 1991 · Employees: 592

Named competitors

MannKind at a glance

Size MannKind (MNKD) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.31B, the 2059th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.07 on 18 Nov 2026.

Performance Over six months the shares gained 25.2%, against -19.0% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue grew 31.7% over the last twelve months (peer median +7.6%); the operating margin is -1.9% (peer median 10.9%).

Valuation It trades at 174.4× forward earnings against a peer median of 15.4× (2nd most expensive of 11).

Capital Return on invested capital runs 11.4 points below its cost of capital (9.3% WACC).

Short interest Short interest is 8.2% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026MNKD 123Peer median 83
Six months, rebased to 100: MannKind against the median of its 20 peers (local-currency closes).

MannKind financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$413M$349M$286M$199M$99.8M
Revenue growth—+22%+43%+99%—
Gross profit$295M$257M$209M$136M$42.3M
EBITDA$18.0M$68.5M$77.6M$16.4M-$62.6M
Net income-$74.8M$5.86M$27.6M-$11.9M-$87.4M
Free cash flow-$78.7M$13.7M$32.4M-$8.54M-$88.3M
Capital expenditure$12.2M$4.57M$9.69M$42.4M$7.59M
Total debt$436M$473M$157M$382M$388M

Quarterly statements and history in the cockpit →

MannKind competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%INVAOCUL688293LBRX301263068760002099002332300181NANOAMPH226950300204GPCR002020AVLNMNKD6-month return →1-month return →
Up and to the right = strong over both horizons. MannKind is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×200×400×INVA688293301263002332300204MNKDRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. MannKind is the large dot.

MannKind competitors and peer comparison

Head to head with its named competitors (MNKD vs LLY vs NOVO-B.CO vs UTHR)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
MannKind MNKD$1.31B+25%+32%-2%174.4×n/a
Lilly (Eli) LLY$1.30T+36%+46%51%29.5×6.5%
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%11.8×-0.5%
United Therapeutics UTHR$24.6B+2%+2%44%23.9×0.3%

How MannKind compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

MannKind against its 20 peers (data as of 18 Nov 2026)
MeasureMNKDPeer medianRank in peer set
1-month return+31.3%-4.3%highest of 20
6-month return+25.2%-19.0%4th highest of 20
Distance from 52-week high-37.5%-38.9%10th highest of 20
Revenue growth (TTM)+31.7%+7.6%2nd highest of 16
Operating margin-1.9%10.9%7th lowest of 16
Forward P/E174.4×15.4×2nd most expensive of 11
ROIC minus cost of capital-11.4 pp-1.8 pp5th lowest of 16
Net debt / EBITDA18.9×0.3×most indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
MannKind MNKDUnited States$1.31B+25%+32%-2%174.4×n/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%9.5×-17.2%+3.9%
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%n/an/an/a
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%48.6×25.9%+23.1%
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%60.7×n/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%n/a10.2%+18.1%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%n/an/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%17.7×-0.4%-1.3%
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%13.0×3.9%+22.8%
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%n/an/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%9.1×2.5%+15.5%
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%n/an/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%522.3×n/an/a
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%11.9×3.4%+27.9%
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%18.6×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%12.1×-9.6%+4.6%
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a

Questions

Who are MannKind's main competitors?
Named competitors: Eli Lilly (LLY), Novo Nordisk (NOVO-B.CO), United Therapeutics (UTHR). The cockpit's measured peer set (industry) also includes Innoviva (INVA), Ocular Therapeutix (OCUL), Windward Bio (WWB), Shanghai OPM Biosciences (688293.SS), LB Pharmaceuticals (LBRX), Guangdong Taienkang Pharmaceutical (301263.SZ).
Is MannKind expensive compared with its peers?
On forward p/e it trades at 174.4× against a peer median of 15.4×, 2nd most expensive of 11 in its peer set.
How has MannKind stock performed?
Over six months to 18 Nov 2026 the shares returned +25.2% against -19.0% for the median peer; over one year -18.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.